This study has been designed to evaluate the quality of haemophilia care in Europe to describe the Sol of European haemophiliacs and to estimate the costs needed to attain these levels of quality of life. About 2040 Patients will be recruited con-seductively from haemophilia comprehensive care centres from 22 Countries. The Study will consist of a Sol Study, Cost-of-Illness-, Cost-Effectiveness- and Cost-Utility-Analysis to perform total costs due to haemophilia, to compare alternative treatments and to determine patient's preferences. Haemophiliac patients from 4 years on will be stratified according to following characteristics: severity of haemophilia, presence of inhibitors, treatment schemes. Clinical and health economic data will be assessed at baseline and prospectively over a 6-month follow-up period. In addition the patients fill in a diary during the follow-up period.
Funding SchemeCSC - Cost-sharing contracts
OX3 9DU Oxford/headington